Clinical trial
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute…
NCT00100152 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00100152 |
|---|---|
| Title | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) |
| Official title | A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | MK0752, (Notch Inhibitor) |
| Enrollment | 50 |
| Start date | Feb 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Dec 24, 2004 |
| Last update posted | May 27, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: